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The Unknowns of Cognitive Enhancement 
Abstract 
“Man is not going to wait passively for millions of years before evolution offers him a better brain.” These 
words are attributed to the 20th century Romanian psychopharmacologist Corneliu Giurgea, an early 
advocate of cognitive enhancement—that is, the use of medications or other brain treatments for 
improving normal healthy cognition. Contemporary attempts at cognitive enhancement involve an array of 
drugs and devices for modifying brain function, such as pills taken by students to help them study, or 
electrical stimulators focused on prefrontal cortex by electronic game players (“e-gamers”) to sharpen 
their skills. What is known about current methods of cognitive enhancement? What specifically do they 
enhance, for whom, and with what risks? We know surprisingly little. 
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Cognitive	enhancement:	Can	science	and	policy	catch	up	with	practice?		 Martha	J.	Farah		“Man	is	not	going	to	wait	passively	for	millions	of	years	before	evolution	offers	him	a	better	brain."		These	words	are	attributed	to	the	20th	Century	Romanian	psychopharmacologist	Corneliu	Giurgea,	an	early	advocate	of	cognitive	enhancement	–	that	is,	the	use	of	medications	for	improving	normal	healthy	cognition.		Contemporary	attempts	at	cognitive	enhancement	involve	an	array	of	drugs	and	devices	for	modifying	brain	function,	from	pills	taken	by	students	to	help	them	study	to	electrical	stimulators	focused	on	prefrontal	cortex	by	e-gamers	to	sharpen	their	skills.		What	do	we	know	about	current	methods	of	cognitive	enhancement?		What	specifically	do	they	enhance,	for	whom,	and	with	what	risks?		We	know	surprisingly	little.		We	do	know	that	stimulants	such	as	amphetamine	and	methylphenidate	(sold	under	trade	names	such	as	Adderall	and	Ritalin,	respectively)	are	widely	used	for	nonmedical	reasons	by	Americans	(1).		However,	it	is	not	known	how	many	of	these	users	are	seeking	cognitive	enhancement,	as	opposed	to	getting	high,	losing	weight	or	some	other	effect.		Student	surveys	suggest	that	cognitive	enhancement	with	stimulants	is	commonplace	on	college	campuses,	where	students	with	prescriptions	sell	surplus	pills	to	other	students,	who	use	them	to	help	study	and	finish	papers	and	projects	(2).		Similar	use	by	college	faculty	and	other	professionals	has	been	documented	but	prevalence	is	unknown	(eg	3,	4).		These	practices	have	been	interpreted	as	paradigm	cases	of	cognitive	enhancement,	generally	aimed	at	improving	executive	function	(EF),	the	ability	to	marshal	cognitive	resources	for	flexible	multitasking	or	focusing,	as	needed.		Because	these	drugs	are	widely	used	to	treat	Attention	Deficit	Hyperactivity	Disorder	(ADHD),	in	which	EF	is	impaired,	they	are	assumed	to	enhance	EF	in	healthy	individuals	as	well.		However,	the	current	evidence	suggests	a	more	complex	state	of	affairs.		The	published	literature	includes	substantially	different	estimates	of	the	effectiveness	of	prescription	stimulants	as	cognitive	enhancers.		A	recent	meta-analysis	suggests	that	the	effect	is	most	likely	real	but	small	for	EF	tests	stressing	inhibitory	control,	and	probably	nonexistent	for	EF	tests	stressing	working	memory	(5).		Why,	then,	do	these	drugs	continue	to	be	used	for	enhancement?		One	possibility	is	that	there	are	important	individual	differences	in	people’s	response	to	them,	with	some	people	benefitting	(2).		In	addition,	stimulants	have	other	effects	for	which	they	may	be	used.		In	a	report	entitled	“Just	How	Cognitive	is	‘Cognitive	Enhancement’?”	sociologist	Scott	Vrecko	interviewed	students	who	used	Adderall	and	found	that	they	emphasized	motivational	and	mood	effects	as	reasons	for	using	the	drugs	for	schoolwork	(6).		Subsequent	research	confirmed	the	role	of	these	noncognitive	factors	for	students	enhancing	with	Adderall;	while	they	differed	minimally	from	nonusers	on	attention	task	performance,	they	exhibited	greater	
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differences	in	motivation	and	worse	study	habits,	along	with	more	depressed	mood	(7).				There	is,	of	course,	a	close	relation	between	cognitive	performance,	on	the	one	hand,	and	motivation,	on	the	other.		Even	if	one’s	laboratory-measured	EF	is	not	appreciably	increased,	one	is	likely	to	get	more	done,	of	better	quality,	if	one	is	feeling	cheerful	and	“into”	the	tasks	at	hand.		Unfortunately,	the	mood-	and	motivation-boosting	abilities	of	stimulants	are	related	to	their	well-known	dependence	potential,	and	that	potential	is	a	significant	safety	concern.	How	likely	is	cognitive	enhancement	use	of	stimulants	to	lead	to	dependence?		The	prevalence	of	drug	dependence	among	enhancement	users	is	not	currently	known.			Another	drug	used	for	cognitive	enhancement	is	modafinil	(trade	name	Provigil).		Best	known	for	its	ability	to	preserve	alertness	and	cognitive	function	under	conditions	of	sleep	deprivation,	it	may	also	enhance	aspects	of	cognition	in	rested	individuals.		As	with	amphetamine,	studies	have	produced	conflicting	results.		A	recent	literature	review	of	the	cognitive	effects	of	modafinil	found	enhancement,	null	effects	and	occasionally	impairment.		Enhancement	was	the	most	common	finding,	especially	in	complex	cognitive	tasks,	although	effect	sizes	were	not	synthesized	through	meta-analysis	to	yield	a	quantitative	summary	measure	of	effectiveness	(8).		A	recent	article,	reporting	a	“striking	increase	in	task	motivation,”	suggested	that	this	may	contribute	to	modafinil’s	value	as	a	cognitive	enhancer	in	the	workplace	(9),	although	motivational	effects	are	inconsistent	across	studies	(8).			Modafinil’s	dependence	potential	is	believed	to	be	low,	although	some	would	not	discount	the	risk	(10).			The	newest	trend	in	cognitive	enhancement	is	the	use	of	transcranial	electric	stimulation	(tES;	11.		In	the	most	widely	used	form	of	tES,	transcranial	direct	current	stimulation	(tDCS),	a	weak	current	flows	between	an	anode	and	a	cathode	placed	on	the	head,	altering	the	resting	potential	of	neurons	in	the	current’s	path.		The	simplicity	and	low	cost	of	tDCS	devices	have	enabled	wide	use	of	the	technology	for	research	and,	increasingly,	for	home	use.		No	epidemiological	data	exist	on	the	use	of	these	devices,	but	the	internet	abounds	with	discussion	and	advice	on	how	to	build	and	use	tDCS	systems.		An	initial	survey	with	a	convenience	sample	recruited	from	internet	sites	indicates	that	cognitive	enhancement	is	the	most	common	reason	for	personal	use	of	tDCS	(12).		Subscribers	to	the	main	tDCS	interest	website	number	in	the	thousands	(12),	but	actual	prevalence	and	related	information	about	tDCS	use	is	unknown.			The	true	cognitive	benefit	of	tDCS	in	normal	healthy	users	is	also	unknown.		As	with	research	on	pharmaceutical	enhancement,	the	published	literature	includes	a	mix	of	findings.	One	recent	attempt	to	synthesize	the	literature	with	meta-analysis	concluded	that	tDCS	has	no	effect	whatsoever	on	a	wide	range	of	cognitive	abilities	(13).	However,	the	methods	of	this	analysis	have	been	criticized	as	unnecessarily	conservative	and	even	biased	(14).		Newer	tES	protocols,	involving	alternating	current	stimulation	(tACS),	random	noise	stimulation	(tRNS)	and	pulsed	stimulation	
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(tPCS),	have	different	physiological	effects	and	hence	potentially	different	psychological	effects,	although	the	empirical	literature	is	still	developing.		TES	is	expanding	beyond	home	hobbyists,	with	new	companies	selling	compact,	visually	appealing,	user-friendly	devices.	These	have	been	exempted	from	regulation	as	medical	devices	by	the	US	FDA.		Foc.us	markets	its	systems	to	gamers	to	improve	attention	and	performance.		Thync,	which	began	selling	its	system	in	June	of	this	year,	is	intended	for	a	much	broader	set	of	lifestyle	uses,	comparable	to	coffee	for	work	and	meditation	for	relaxation.	At	present	there	is	little	scientific	evidence	for	or	against	the	effectiveness	of	these	specific	systems,	nor	is	there	evidence	concerning	physiological	and	psychological	effects	of	regular	use	over	months	or	years	in	humans	or	in	animals.		To	summarize	the	state	of	empirical	knowledge	regarding	cognitive	enhancement,	it	remains	difficult	to	say	what	cognitive	benefits	these	practices	offer,	in	the	lab	let	alone	in	the	classroom	or	workplace,	and	attendant	risks	are	even	harder	to	gauge.		While	surveys	have	estimated	the	number	of	college	students	using	stimulants	for	enhancement,	little	is	known	about	other	people	and	other	practices.		Without	knowing	more	about	the	prevalence,	risks	and	benefits	of	these	brain	interventions,	it	is	difficult	to	formulate	useful	policy.		Why	are	we	so	ignorant?		Several	factors	seem	to	be	at	play.		The	majority	of	studies	of	enhancement	effectiveness	have	been	carried	out	on	small	samples,	rarely	more	than	50	subjects,	which	limits	their	power.		Furthermore,	cognitive	tasks	typically	lend	themselves	to	a	variety	of	different	but	reasonable	outcome	measures,	such	as	overall	errors,	specific	types	of	errors	(eg,	false	alarms)	and	response	times.		In	addition	there	is	usually	more	than	one	possible	statistical	approach	to	analyzing	the	enhancement	effect.		Small	samples	and	flexibility	in	design	and	analysis	raise	the	likelihood	of	published	false	positives	(15).		In	addition,	pharmacologic	and	electric	enhancements	may	differ	in	effectiveness	depending	on	the	biological	and	psychological	traits	of	the	user,	which	complicates	the	effort	to	understand	the	true	enhancement	potential	of	these	technologies.	Industry	is	understandably	unmotivated	to	take	on	the	expense	of	appropriate	large-scale	trials	of	enhancement,	given	that	the	stimulants	used	are	illegally	diverted	and	tES	devices	can	be	sold	without	such	evidence.		The	inferential	step	from	laboratory	effect	to	real	world	benefit	adds	another	layer	of	challenge.		Finally,	given	that	enhancements	would	likely	be	used	for	years,	long-term	effectiveness	and	safety	are	essential	concerns	but	are	particularly	difficult	and	costly	to	determine.		As	a	result,	the	only	large-scale	trial	we	may	see	is	the	enormous	but	uncontrolled	and	poorly	monitored	trial	of	people	using	these	drugs	and	devices	on	their	own.			 	
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